• Pfizer Inc., of New York, issued a statement regarding the use of Prevnar 13 (pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]) in adults, 50 and older. The pharma firm said it believes Prevnar 13 should be recommended for adults in that age group, given the current burden of pneumococcal disease.